Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC)

Journal of Ovarian Research

Volumn 4, Issue 1, 2011, Pages

  Muenyi, Clarisse S ^a   States, Vanessa A ^a   Masters, Joshua H ^a   Fan, Teresa W ^a,b   Helm, C William ^c   States, J Christopher ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cisplatin; HIPEC; hyperthermia; metastatic human ovarian cancer; MSH2; p53; platinum accumulation; sodium arsenite; XPA; XPC

Indexed keywords

ARSENIC TRIOXIDE; ARSENITE SODIUM; CEFAZOLIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PLATINUM; PROTEIN MSH2; PROTEIN P53; XERODERMA PIGMENTOSUM GROUP A PROTEIN; XERODERMA PIGMENTOSUM GROUP C PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CONCENTRATION (PARAMETERS); DNA DAMAGE; DRUG ACCUMULATION; DRUG EFFICACY; DRUG SENSITIZATION; ENZYME INHIBITION; EPITHELIAL OVARIAN CANCER; EXCISION REPAIR; FEMALE; HEART; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPERTHERMIA; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; IMMUNOCYTOCHEMISTRY; KIDNEY; LIVER; METASTASIS; MOUSE; NONHUMAN; OVARY CANCER; PERFUSION; PERITONEUM METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 79959355146     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-4-9     Document Type: Article

References (57)

1. Cancer statistics, 2009. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun, CA Cancer J Clin 2009 59 225 249 10.3322/caac.20006 19474385
2. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. DK Armstrong B Bundy L Wenzel HQ Huang R Baergen S Lele LJ Copeland JL Walker RA Burger, N Engl J Med 2006 354 34 43 10.1056/NEJMoa052985 16394300 (Pubitemid 43048949)
3. Treatment goals in ovarian cancer. RF Ozols, Int J Gynecol Cancer 2005 15 Suppl 1 3 11 15839952 (Pubitemid 40696471)
4. Intraperitoneal chemotherapy in the management of malignant disease. M Markman, Expert Rev Anticancer Ther 2001 1 142 148 10.1586/14737140.1.1.142 12113122 (Pubitemid 34679404)
5. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. V van d V van d FA Zoetmulder AR van Goethem O van T WW ten Bokkel Huinink JH Beijnen H Bartelink AC Begg, Eur J Cancer 1998 34 148 154 10.1016/S0959-8049(97)00370-5 9624250 (Pubitemid 28123393)
6. National Cancer Institute-United States strategy regarding intraperitoneal chemotherapy for ovarian cancer. EL Trimble MC Christian, Int J Gynecol Cancer 2008 18 Suppl 1 26 28 18336395 (Pubitemid 351389049)
7. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. CW Helm, Oncologist 2009 14 683 694 10.1634/theoncologist.2008-0275 19608639
8. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: Results from a Chinese center. XJ Yang Y Li Y Yonemura, J Surg Oncol 2010 101 457 464 10.1002/jso.21519 20401915
9. Hyperthermic intraperitoneal chemotherapy added to the treatment of ovarian cancer. A review of achieved results and complications. E Dovern IH de Hingh VJ Verwaal WJ van Driel SW Nienhuijs, Eur J Gynaecol Oncol 2010 31 256 261 21077465
10. Biochemical mechanisms of cisplatin cytotoxicity. V Cepeda MA Fuertes J Castilla C Alonso C Quevedo JM Perez, Anticancer Agents Med Chem 2007 7 3 18 10.2174/187152007779314044 17266502 (Pubitemid 46062402)
11. Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. CW Helm RE Bristow S Kusamura D Baratti M Deraco, J Surg Oncol 2008 98 283 290 10.1002/jso.21083 18726895
12. Selective lethal effect of supranormal temperatures on human neoplastic cells. BC Giovanella JS Stehlin Jr AC Morgan, Cancer Res 1976 36 3944 3950 975042
13. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. G Los MJ van Vugt HM Pinedo, Br J Cancer 1994 69 235 241 10.1038/bjc.1994.45 8297720 (Pubitemid 24046543)
14. Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. MH Cohen S Hirschfeld HS Flamm A Ibrahim JR Johnson JJ O'Leary RM White GA Williams R Pazdur, Oncologist 2001 6 4 11 11700386 (Pubitemid 32155810)
15. Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role. CW Helm JC States, J Ovarian Res 2009 2 2 10.1186/1757-2215-2-2 19144189
16. Experimental study on antitumor effect of arsenic trioxide in combination with cisplatin or doxorubicin on hepatocellular carcinoma. W Wang SK Qin BA Chen HY Chen, World J Gastroenterol 2001 7 702 705 11819858 (Pubitemid 32994424)
17. Enhancement of radiation response in human cervical cancer cells in vitro and in vivo by arsenic trioxide (As2O3). YJ Chun IC Park MJ Park SH Woo SI Hong HY Chung TH Kim YS Lee CH Rhee SJ Lee, FEBS Lett 2002 519 195 200 10.1016/S0014-5793(02)02765-5 12023044 (Pubitemid 34522018)
18. Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours. RJ Griffin H Monzen BW Williams H Park SH Lee CW Song, Int J Hyperthermia 2003 19 575 589 10.1080/0265673031000124316 14756449 (Pubitemid 37406668)
19. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. R Uslu UA Sanli C Sezgin B Karabulut E Terzioglu SB Omay E Goker, Clin Cancer Res 2000 6 4957 4964 11156257 (Pubitemid 32110442)
20. Sensitivity to sodium arsenite in human melanoma cells depends upon susceptibility to arsenite-induced mitotic arrest. SC McNeely AC Belshoff BF Taylor TW Fan MJ McCabe Jr AR Pinhas JC States, Toxicol Appl Pharmacol 2008 229 252 261 10.1016/j.taap.2008.01.020 18328521
21. Arsenite-induced mitotic death involves stress response and is independent of tubulin polymerization. BF Taylor SC McNeely HL Miller JC States, Toxicol Appl Pharmacol 2008 230 235 246 10.1016/j.taap.2008.02.030 18485433
22. Metabolism and the paradoxical effects of arsenic: carcinogenesis and anticancer. X Cui Y Kobayashi M Akashi R Okayasu, Curr Med Chem 2008 15 2293 2304 10.2174/092986708785747526 18781951
23. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. AJ Murgo, Oncologist 2001 6 Suppl 2 22 28 11346681 (Pubitemid 32405846)
24. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. H Maeda S Hori H Nishitoh H Ichijo O Ogawa Y Kakehi A Kakizuka, Cancer Res 2001 61 5432 5440 11454688 (Pubitemid 32694923)
25. Arsenic trioxide (As(2)O(3)) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo. J Zhang B Wang, Gynecol Oncol 2006 103 199 206 10.1016/j.ygyno.2006.02.037 16624393 (Pubitemid 44374690)
26. Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Y Nakagawa Y Akao H Morikawa I Hirata K Katsu T Naoe N Ohishi K Yagi, Life Sci 2002 70 2253 2269 10.1016/S0024-3205(01)01545-4 12005185 (Pubitemid 34251296)
27. Arsenic trioxide induces apoptosis in cisplatin-sensitive and -resistant ovarian cancer cell lines. B Kong S Huang W Wang D Ma X Qu J Jiang X Yang Y Zhang B Wang B Cui Q Yang, Int J Gynecol Cancer 2005 15 872 877 10.1111/j.1525-1438.2005.00251.x 16174238 (Pubitemid 41783095)
28. Interaction of arsenic(III) with nucleotide excision repair in UV-irradiated human fibroblasts. A Hartwig UD Groblinghoff D Beyersmann AT Natarajan R Filon LH Mullenders, Carcinogenesis 1997 18 399 405 10.1093/carcin/18.2.399 9054635 (Pubitemid 28132435)
29. Impact of arsenic on nucleotide excision repair: XPC function, protein level, and gene expression. M Nollen F Ebert J Moser LH Mullenders A Hartwig T Schwerdtle, Mol Nutr Food Res 2009
30. Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. EM Leslie A Haimeur MP Waalkes, J Biol Chem 2004 279 32700 32708 10.1074/jbc.M404912200 15161912 (Pubitemid 39014729)
31. Mechanisms of resistance to cisplatin and carboplatin. DJ Stewart, Crit Rev Oncol Hematol 2007 63 12 31 10.1016/j.critrevonc.2007.02.001 17336087 (Pubitemid 46810280)
32. Dose translation from animal to human studies revisited. S Reagan-Shaw M Nihal N Ahmad, FASEB J 2008 22 659 661 17942826 (Pubitemid 351348146)
33. Measurement of protein using bicinchoninic acid. PK Smith RI Krohn GT Hermanson AK Mallia FH Gartner MD Provenzano EK Fujimoto NM Goeke BJ Olson DC Klenk, Anal Biochem 1985 150 76 85 10.1016/0003-2697(85)90442-7 3843705 (Pubitemid 16258399)
34. Photo-cross-linking of XPC-Rad23B to cisplatin-damaged DNA reveals contacts with both strands of the DNA duplex and spans the DNA adduct. TM Neher NI Rechkunova OI Lavrik JJ Turchi, Biochemistry 2010 49 669 678 10.1021/bi901575h 20028083
35. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. M Dabholkar J Vionnet F Bostick-Bruton JJ Yu E Reed, J Clin Invest 1994 94 703 708 10.1172/JCI117388 8040325 (Pubitemid 24251002)
36. Regulation of DNA damage recognition and nucleotide excision repair: another role for p53. JM Ford, Mutat Res 2005 577 195 202 15927209 (Pubitemid 41225499)
37. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. D Fink H Zheng S Nebel PS Norris S Aebi TP Lin A Nehmé RD Christen M Haas CL MacLeod SB Howell, Cancer Res 1997 57 1841 1845 9157971 (Pubitemid 27209707)
38. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. KC Jensen MR Mariappan GV Putcha A Husain N Chun JM Ford I Schrijver TA Longacre, Am J Surg Pathol 2008 32 1029 1037 10.1097/PAS.0b013e31816380c4 18469706
39. Toxicity of platinum compounds. JT Hartmann HP Lipp, Expert Opin Pharmacother 2003 4 889 901 10.1517/14656566.4.6.889 12783586 (Pubitemid 36722480)
40. Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study. A Gesson-Paute G Ferron F Thomas EC de Lara E Chatelut D Querleu, Ann Surg Oncol 2008 15 339 344 10.1245/s10434-007-9571-9 17943387
41. Cardiovascular effects of systemic cancer treatment. E Senkus J Jassem, Cancer Treat Rev 2010
42. Arsenic trioxide - An old drug rediscovered. A Emadi SD Gore, Blood Rev 2010 24 191 199 10.1016/j.blre.2010.04.001 20471733
43. Arsenic trioxide: safety issues and their management. WY Au YL Kwong, Acta Pharmacol Sin 2008 29 296 304 10.1111/j.1745-7254.2008.00771.x 18298894
44. Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC). S Zeamari B Floot V van d FA Stewart, Anticancer Res 2003 23 1643 1648 12820435 (Pubitemid 36754141)
45. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. A Berchuck MF Kohler JR Marks R Wiseman J Boyd RC Bast Jr, Am J Obstet Gynecol 1994 170 246 252 8296829 (Pubitemid 24084061)
46. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. NA Jones J Turner AJ McIlwrath R Brown C Dive, Mol Pharmacol 1998 53 819 826 9584207 (Pubitemid 28244068)
47. The impact of p53 status on cellular sensitivity to antifolate drugs. X Lu J Errington NJ Curtin J Lunec DR Newell, Clin Cancer Res 2001 7 2114 2123 11448931 (Pubitemid 32994852)
48. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. R Brown C Clugston P Burns A Edlin P Vasey B Vojtesek SB Kaye, Int J Cancer 1993 55 678 684 10.1002/ijc.2910550428 8406999 (Pubitemid 23328959)
49. Prolonged wild-type p53 protein accumulation and cisplatin resistance. EM Yazlovitskaya RD DeHaan DL Persons, Biochem Biophys Res Commun 2001 283 732 737 10.1006/bbrc.2001.4849 11350044 (Pubitemid 32924639)
50. The costs of using unauthenticated, over-passaged cell lines: how much more data do we need? P Hughes D Marshall Y Reid H Parkes C Gelber, Biotechniques 2007 43 575 577 10.2144/000112598 18072586
51. Why did p53 gene therapy fail in ovarian cancer? AG Zeimet C Marth, Lancet Oncol 2003 4 415 422 10.1016/S1470-2045(03)01139-2 12850192 (Pubitemid 36833683)
52. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. JA Engelman, Nat Rev Cancer 2009 9 550 562 10.1038/nrc2664 19629070
53. Platinum resistance: the role of DNA repair pathways. LP Martin TC Hamilton RJ Schilder, Clin Cancer Res 2008 14 1291 1295 10.1158/1078-0432.CCR- 07-2238 18316546 (Pubitemid 351413906)
54. Interrogation of nucleotide excision repair capacity: Impact on platinum-based cancer therapy. JN Earley J Turchi, Antioxid Redox Signal 2010
55. Mismatch repair protein deficiency compromises cisplatin-induced apoptotic signaling. RP Topping JC Wilkinson KD Scarpinato, J Biol Chem 2009 284 14029 14039 10.1074/jbc.M809303200 19286655
56. MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition. X Ding AB Mohd Z Huang T Baba MQ Bernardini HK Lyerly A Berchuck SK Murphy AB Buermeyer GR Devi, Br J Cancer 2009 101 269 277 10.1038/sj.bjc.6605180 19603033
57. Mismatch repair status and the response of human cells to cisplatin. E Pani L Stojic M El-Shemerly J Jiricny S Ferrari, Cell Cycle 2007 6 1796 1802 10.4161/cc.6.14.4472 17622800 (Pubitemid 47327934)